Two phase 3 clinical trials evaluating Beovu in patients with diabetic macular edema had positive visual acuity results with a well-tolerated safety profile, according to a press release from Novartis.
Beovu (brolucizumab) 6 mg was assessed against aflibercept 2 mg in both trials.
In the KITE trial at 2 years, a majority of patients who successfully completed an initial 12-week cycle after a loading phase were maintained on a 12- or 16-week dosing interval. Results for Beovu were consistent with those seen at 1 year, with maintenance of best corrected (Read more...)